Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Receivables (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Receivables readings, the most recent being $8.5 million for Q4 2025.

  • On a quarterly basis, Receivables rose 10.04% to $8.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.5 million, a 10.04% increase, with the full-year FY2025 number at $6.9 million, up 3.55% from a year prior.
  • Receivables hit $8.5 million in Q4 2025 for Enanta Pharmaceuticals, up from $6.9 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $27.6 million in Q4 2021 to a low of $6.6 million in Q3 2024.
  • Median Receivables over the past 5 years was $13.2 million (2023), compared with a mean of $14.4 million.
  • Biggest five-year swings in Receivables: increased 15.93% in 2021 and later plummeted 63.81% in 2023.
  • Enanta Pharmaceuticals' Receivables stood at $27.6 million in 2021, then decreased by 18.31% to $22.6 million in 2022, then plummeted by 63.81% to $8.2 million in 2023, then fell by 5.57% to $7.7 million in 2024, then increased by 10.04% to $8.5 million in 2025.
  • The last three reported values for Receivables were $8.5 million (Q4 2025), $6.9 million (Q3 2025), and $8.3 million (Q2 2025) per Business Quant data.